Yeah. So there is no, so the spectrum of toxicity of immune checkpoint inhibitors is quite different than the one that is related with ADC. So it is not the same mechanism of toxicity and there is no overlapping toxicity, but there are some organs that can have immune-related toxicity and also toxicity linked to the ADC, for example, pneumonitis. So for these overlapping organs that can be touched by adverse events by both modalities, we have to be really vigilant...
Yeah. So there is no, so the spectrum of toxicity of immune checkpoint inhibitors is quite different than the one that is related with ADC. So it is not the same mechanism of toxicity and there is no overlapping toxicity, but there are some organs that can have immune-related toxicity and also toxicity linked to the ADC, for example, pneumonitis. So for these overlapping organs that can be touched by adverse events by both modalities, we have to be really vigilant. So I’m thinking of pneumonitis, but also of rash. So this, we will need some careful dose optimization and better monitoring of the disease and see with some sequencing if it can influence tolerability.
This transcript is AI-generated. While we strive for accuracy, please verify this copy with the video.